Evaluation of the early-phase [18F]AV45 PET as an optimal surrogate of [18F]FDG PET in ageing and Alzheimer’s clinical syndrome

Autor: Vanhoutte, Matthieu, Landeau, Brigitte, Sherif, Siya, de la Sayette, Vincent, Dautricourt, Sophie, Abbas, Ahmed, Manrique, Alain, Chocat, Anne, Chételat, Gaël
Jazyk: angličtina
Předmět:
Optimization
MRI
Magnetic resonance imaging
aMCI
amnestic mild cognitive impairment
Aβ
β-amyloid
Computer applications to medicine. Medical informatics
R858-859.7
BACC
Balanced accuracy
SVM
Support vector machine
Alz-CS
Alzheimer’s clinical syndrome patients
AD
Alzheimer’s disease
PVE
partial volume effect
PET
positron emission tomography
MMSE
Mini-mental state examination
CD
Critical difference
Alzheimer Disease
Fluorodeoxyglucose F18
Humans
Neurodegeneration
[18F]AV45
18F-Florbetapir
RC346-429
eAV45
early-phase [18F]AV45 PET
lAV45
late-phase [18F]AV45 PET
AD-d
dementia due to AD
Aniline Compounds
DK
Desikan-Killiany
Regular Article
FWE
Familywise error
eHC
Elderly healthy controls
Proxy
[18F]FDG PET
yHC
young healthy controls
ROIs
Regions of interest
FCSRT
free and cued selective reminding test
[18F]FDG
[18F]fluorodeoxyglucose
Positron-Emission Tomography
GM
Gray matter
Early-phase [18F]AV45 PET
SUVR
standardized uptake value ratio
Neurology. Diseases of the nervous system
CBF
cerebral blood flow
Biomarkers
Zdroj: NeuroImage: Clinical, Vol 31, Iss, Pp 102750-(2021)
NeuroImage : Clinical
ISSN: 2213-1582
DOI: 10.1016/j.nicl.2021.102750
Popis: Highlights • Exhaustive vertex-wise quantitative analyses to validate eAV45 as an optimal proxy for 18F-FDG PET. • Optimal early time frame 0–4 min maximizes both within- and inter-subject correlations of eAV45 with 18F-FDG PET. • Optimal early time frame 0–4 min minimizes both within- and inter-subject correlations of eAV45 with lAV45. • Balanced accuracies of neurodegenerative pattern overlap of both 18F-FDG PET and eAV45 are maximal with pons scaling. • Classification performance between clinical subgroups was similar for both eAV45 and [18F]FDG PET.
Dual-phase [18F]AV45 positron emission tomography (PET) is highly promising in the assessment of neurodegenerative diseases, allowing to obtain information on both neurodegeneration (early-phase; eAV45) and amyloid deposition (late-phase; lAV45) which are highly complementary; yet eAV45 needs further evaluation. This study aims at validating eAV45 as an optimal proxy of [18F]FDG PET in a large mixed-population of healthy ageing and Alzheimer’s clinical syndrome participants (n = 191) who had [18F]FDG PET, eAV45 and lAV45 scans. We found early time frame 0–4 min to give maximal correlation with [18F]FDG PET and minimal correlation with lAV45. Moreover, maximal overlap of [18F]FDG PET versus eAV45 associations with clinical diagnosis and cognition was obtained with pons scaling. Across reference regions, classification performance between clinical subgroups was similar for both eAV45 and [18F]FDG PET. These findings highlight the optimal use of eAV45 to assess neurodegeneration as a validated proxy of [18F]FDG PET. On top of this purpose, this study showed that combined [18F]AV45 PET dual-biomarker even outperformed [18F]FDG PET or lAV45 alone.
Databáze: OpenAIRE
Externí odkaz: